

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

NCT06379542

Status	RECRUITING
Phase	Phase 3
Sponsor	Valenta Pharm JSC
Enrollment	252 participants

Key Eligibility Criteria

Inclusion (48)

- Patient signing the Informed Consent Form and parent/adoptive parent signing the Parent/Adoptive Informed Consent Form.
- Male and female children between the ages of 6 and 17 years 10 months inclusive at the time of screening.
- Clinical diagnosis of acute respiratory viral upper respiratory tract infection (J00-J06 according to ICD-10) or acute bronchitis (J20, J21 according to ICD-10).
- Onset of disease symptoms no more than 3 days prior to screening.
- Presence of dry non-productive cough in the patient.

... and 43 more (see full listing online)

Exclusion (4)

- Identification of a confirmed case of COVID-19.
- Ineffectiveness of therapy - persistence or increase in cough attack frequency e1 by Visit 3 (Day 8-9) compared to Visit 1 (Day 1).
- Adverse events (AEs) requiring withdrawal of study drug/placebo.
- Occurrence of any disease or condition during the study that, in the opinion of the investigator, worsens the patient's prognosis and makes it impossible for the patient to continue participating in the clinical trial.

Locations (6 total)

City Pediatric Outpatient Clinic number 5, Perm, Russia

Professors' Clinic LLC., Perm, Russia

St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 44", Saint Petersburg, Russia

... and 3 more locations